Kymera Therapeutics, Inc. is a clinical-stage biopharmaceutical company dedicated to transforming the treatment of human diseases through the development of innovative, highly differentiated medicines. It focuses on discovering and developing novel small-molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body’s natural protein degradation system. The company leverages targeted protein degradation (TPD) to develop medicines that address critical health challenges and have the potential to significantly improve patients lives. Its pipeline emphasizes oral small-molecule degraders, offering a new generation of convenient and highly effective therapies. The company was founded by Bruce Lee Booth and Nello Mainolfi on September 29, 2015 and is headquartered in Watertown, MA.
Sector:
Health Technology
Industry:
Biotechnology
Employees:
238
Frequently Asked Questions
Market cap, also known as market capitalization, is the total market value of a company. It's calculated by multiplying the current market price by the total number of shares outstanding. Kymera Therapeutics Inc market cap is $9.84B.
52 week high is the highest price of a stock in the past 52 weeks, or one year. Kymera Therapeutics Inc 52 week high is $142.92 as of November 22, 2026.
52 week low is the lowest price of a stock in the past 52 weeks, or one year. Kymera Therapeutics Inc 52 week low is $63.69 as of November 22, 2026.
Kymera Therapeutics Inc stock price today is $115.31.
Kymera Therapeutics Inc stock price yesterday was $119.39.
The Price-to-Earnings (or P/E) ratio is a commonly used tool for valuing a company. It's calculated by dividing the current share price by the earnings per share (or EPS). It can also be calculated by dividing the company's Market Cap by the Net Profit. Kymera Therapeutics Inc's P/E ratio is -31.86.
The Price-to-Book (P/B) ratio is a commonly used tool for valuing a company. It's calculated by dividing a company's market capitalization by its book value. Kymera Therapeutics Inc P/B ratio is 6.094.
The 50-day moving average is a frequently used data point by active investors and traders to understand the trend of a stock. It's calculated by averaging the closing stock price over the previous 50 trading days. Kymera Therapeutics Inc 50-day moving average is $117.57.